Bulevirtide Clinical Trials

5 actively recruiting trials

▼ -1 trial since August 2026

Also known as: BJT-778, Hepcludex

Pipeline

Phase 2/3: 1

Top Sponsors

Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico2
Research Center of Periodontal-Systemic Interactions1
Mirum Pharmaceuticals, Inc.1
Karolinska University Hospital1

Indications

Liver Disease5
Hepatitis D3
Chronic Hepatitis D2
Periodontitis1
Hepatitis B, Chronic1

Other5 trials

Effectiveness and Safety of Bulevirtide (BLV) Therapy in Patients With Chronic Hepatitis Delta (CHD) in Italy (D-SHIELD)

Immunological and Virological Characterization of Patients With Chronic HBV-HDV Infection: Outcomes and Response to Bulevirtide Treatment

Oral-Periodontal Evaluation and Assessment of Oral Fluid Biomarkers in Patients With Hepatitis B+D

Study to Evaluate Efficacy, Safety and Biomarkers of Bulevirtide Treatment in Chronic Hepatitis D Patients

Study to Evaluate Switching to Brelovitug for the Treatment of CHD in Participants Receiving Bulevirtide

Phase 2/3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.